about
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United StatesClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CInpatient Management of Opioid Use Disorder: A Review for Hospitalists.Hepatitis C genotype 3 disease.Suboptimal Addiction Interventions for Patients Hospitalized with Injection Drug Use-Associated Infective Endocarditis.HIV/HCV Co-infection: Overcoming Barriers to Treatment.Reimagining long-term antibiotics in persons who inject drugs: Time to shift the status quo?Pulmonary Zygomycosis in a Non-neutropenic Patient With Myelodysplastic Syndrome on Lenalidomide
P50
Q26749246-776D91D7-F895-4453-A23F-F2EF59EACB1DQ28080225-AAE9DF41-6CD6-41BA-B635-42371D332300Q30234596-0A8233F4-4241-4117-A9F8-25447B8B39DFQ30244065-222FC923-B24E-45D3-B5A0-97002CBA092BQ38644630-27D248F9-50EB-4784-B3CB-BC4CB8954751Q40748093-8712DE3A-3217-41E3-A3FA-253CBC6A9EA1Q44464680-52360FEF-0011-4BD9-B2E3-9F60A0C107CBQ60585361-604CA705-D3F3-4861-8957-42CAE418CF5B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elana Rosenthal
@ast
Elana Rosenthal
@en
Elana Rosenthal
@es
Elana Rosenthal
@nl
Elana Rosenthal
@sl
type
label
Elana Rosenthal
@ast
Elana Rosenthal
@en
Elana Rosenthal
@es
Elana Rosenthal
@nl
Elana Rosenthal
@sl
prefLabel
Elana Rosenthal
@ast
Elana Rosenthal
@en
Elana Rosenthal
@es
Elana Rosenthal
@nl
Elana Rosenthal
@sl
P106
P21
P31
P496
0000-0001-7234-4871